Sequence-specific in vivo cell targeting
AssigneesG+FLAS Life Sciences, Seoul National University R&Db Foundation
InventorsSungyong IN, Sunghwa CHOE, Mi Jin PARK, Aiden Y. PARK, Jung Hak LIM, Dong Wook KIM, Youngdong YOO, Jongjin PARK
Life of this patent
Estimating the term…
Abstract
Enhanced, specific nucleic acid targeting complexes comprising endo and exonuclease activity, and related methods that allow both targeted degradation of specific and/or non-specific nucleic acids in vivo and specific temporal regulation of nuclease activity to prevent off-target activity are disclosed herein. Through practice of the disclosure, nucleic acids, and cells harboring them, such as cancer cells or pathogens, are selectively degraded in vivo.
Claims20
A method of selectively inducing cell death of a cell in a tissue of a subject in need thereof, the method comprising:
- a) administering to the subject a chimeric polypeptide comprising a first domain comprising sequence-specific endonuclease activity and a second domain comprising exonuclease activity, and a guide nucleic acid comprising a sequence complementary to a target nucleic acid in the cell;
- and
- b) cleaving the target nucleic acid, thereby inducing cell death.
Dependencies are inferred from the claim text.